EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy

Mitchell C Lock iD, Kimberley J Botting, Beth J Allison iD, Youguo Niu iD, Sage G Ford, Michael P Murphy, Sandra Orgeig, Dino A Giussani iD, Janna L Morrison iD

The Journal of Physiology · 2023-08 · 601 (16) · 3647-3665

DOI: 10.1113/jp284786 ↗

At a glance

Journal article in The Journal of Physiology, published online on 2023-07-19. Written by Mitchell C Lock and 8 co-authors. Institution: Early Origins of Adult Health Research Group, Health and Biomedical Innovation, UniSA: Clinical and Health Science, University of South Australia, Ad…. Major MEDLINE topics: Antioxidants, Hypoxia, Organophosphorus Compounds. Cited 24 times so far (Crossref); 62 references. The full text is freely available (open access, CC BY 4.0). Funded by: British Heart Foundation, Medical Research Council.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Chronic fetal hypoxaemia is a common pregnancy complication that increases the risk of infants experiencing respiratory complications at birth. In turn, chronic fetal hypoxaemia promotes oxidative stress, and maternal antioxidant therapy in animal models of hypoxic pregnancy has proven to be protective with regards to fetal growth and cardiovascular development. However, whether antenatal antioxidant therapy confers any benefit on lung development in complicated pregnancies has not yet been investigated. Here, we tested the hypothesis that maternal antenatal treatment with MitoQ will protect the developing lung in hypoxic pregnancy in sheep, a species with similar fetal lung developmental milestones as humans. Maternal treatment with MitoQ during late gestation promoted fetal pulmonary surfactant maturation and an increase in the expression of lung mitochondrial complexes III and V independent of oxygenation. Maternal treatment with MitoQ in hypoxic pregnancy also increased the expression of genes regulating liquid reabsorption in the fetal lung. These data support the hypothesis tested and suggest that MitoQ as an antenatal targeted antioxidant treatment may improve lung maturation in the late gestation fetus. image Key points Chronic fetal hypoxaemia promotes oxidative stress, and maternal antioxidant therapy in hypoxic pregnancy has proven to be protective with regards to fetal growth and cardiovascular development. MitoQ is a targeted antioxidant that uses the cell and the mitochondrial membrane potential to accumulate within the mitochondria. Treatment of healthy or hypoxic pregnancy with MitoQ, increases the expression of key molecules involved in surfactant maturation, lung liquid reabsorption and in mitochondrial proteins driving ATP synthesis in the fetal sheep lung. There were no detrimental effects of MitoQ treatment alone on the molecular components measured in the present study, suggesting that maternal antioxidant treatment has no effect on other components of normal maturation of the surfactant system.

Subjects

MeSH terms (MEDLINE)

AntioxidantsHypoxiaOrganophosphorus CompoundsHumansInfant, NewbornPregnancyFemaleAnimalsSheepLungSurface-Active AgentsUbiquinone

Author keywords

antioxidantfetal growth restrictionfetushypoxialung developmentsurfactant

Substances

AntioxidantsmitoquinoneSurface-Active AgentsOrganophosphorus CompoundsUbiquinone

Authors and institutions

  • Early Origins of Adult Health Research Group, Health and Biomedical Innovation, UniSA: Clinical and Health Science, University of South Australia, Adelaide, South Australia, Australia.
  • Department of Physiology, Development & Neuroscience, University of Cambridge, Cambridge, UK.
  • MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
  • UniSA: Clinical and Health Science, University of South Australia, Adelaide, South Australia, Australia.

ORCID profiles: Mitchell C Lock, Beth J Allison, Youguo Niu, Dino A Giussani, Janna L Morrison

Funding

  • British Heart Foundation
  • Medical Research Council

Cite

APA

Lock, M. C., Botting, K. J., Allison, B. J., Niu, Y., Ford, S. G., Murphy, M. P., Orgeig, S., Giussani, D. A., & Morrison, J. L. (2023). MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy. The Journal of Physiology, 601(16), 3647-3665. https://doi.org/10.1113/jp284786

Vancouver

Lock MC, Botting KJ, Allison BJ, Niu Y, Ford SG, Murphy MP, et al. MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy. The Journal of Physiology. 2023;601(16):3647-3665. doi:10.1113/jp284786

BibTeX
@article{Lock2023,
  author = {Lock, Mitchell C and Botting, Kimberley J and Allison, Beth J and Niu, Youguo and Ford, Sage G and Murphy, Michael P and Orgeig, Sandra and Giussani, Dino A and Morrison, Janna L},
  title = {MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy},
  journal = {The Journal of Physiology},
  year = {2023},
  volume = {601},
  number = {16},
  pages = {3647--3665},
  doi = {10.1113/jp284786}
}
Start for free →